摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-formylphenyl)-2-nitrobenzenesulfonamide | 911312-96-4

中文名称
——
中文别名
——
英文名称
N-(2-formylphenyl)-2-nitrobenzenesulfonamide
英文别名
——
N-(2-formylphenyl)-2-nitrobenzenesulfonamide化学式
CAS
911312-96-4
化学式
C13H10N2O5S
mdl
——
分子量
306.299
InChiKey
OZBZTBJQMFZONW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    157-159 °C
  • 沸点:
    515.3±60.0 °C(predicted)
  • 密度:
    1.515±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    117
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:EP1867639A1
    公开(公告)日:2007-12-19
    Urea derivatives represented by the following general formula (I) : which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group, an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group, M1 is a single bond, a C1-4 alkylene group or the like, Y is N or CRF (in the formula, and RF represents a hydrogen atom, a C1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.
    以下一般公式(I)所代表的尿素衍生物,具有V2受体的激动作用,可用作治疗或预防尿崩症、夜尿、夜间遗尿、膀胱过度活动等药物。在公式中,R1代表氢原子或可能具有取代基团的C1-6烷基;R2是氢原子或C1-6烷基;R3是氢原子、C1-6烷基或其他基团;R4、R5和R6独立地是氢原子、卤素原子或其他基团;R7是氢原子、可能具有取代基团的杂环烷基、C3-8环烷基、可能具有取代基团的氨基或可能具有取代基团的C1-6烷氧基;M1是单键、C1-4烷基或其他基团;Y是N或CRF(在公式中,RF代表氢原子、C1-6烷基或其他基团),或其药学上可接受的盐、前药、包含相同成分的药物组合物及其药用。
  • Scandium-Catalyzed Cascade Cyclization to Produce Cyclobutane-Fused Tetrahydroquinoline, Chromane, Thiochromane, and Tetrahydronaphthalene Derivatives
    作者:Shun-ichi Nakano、Kazumi Kakugawa、Tetsuhiro Nemoto、Yasumasa Hamada
    DOI:10.1002/adsc.201400020
    日期:2014.6.16
    We have succeeded in the highly diastereoselective synthesis of cyclobutanefused multi‐cyclic compounds using a scandium‐catalyzed cascade cyclization. Using 3–10 mol% of scandium(III) triflate [Sc(OTf)3], various cyclobutanefused tetrahydroquinoline derivatives as well as its chromane, thiochromane, and tetrahydronaphthalene analogues were obtained in good to excellent yields. Derivatizations of
    我们已经通过scan催化的级联环化成功地完成了非对映选择性的环丁烷稠合多环化合物的合成。使用3-10 mol%的三氟甲磺酸([Sc(OTf)3 ],可以良好的收率获得各种环丁烷稠合的四氢喹啉衍生物,以及其色烷,硫代苯并四氢萘类似物。还讨论了反应产物的衍生化以及合理的反应机理。
  • Urea derivative, medicinal composition containing the same, and medicinal use of these
    申请人:Suzuki Ritsu
    公开号:US20080161294A1
    公开(公告)日:2008-07-03
    Urea derivatives represented by the following general formula (I): which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R 1 represents a hydrogen atom or a C 1-6 alkyl group which may have a substituent, R 2 is a hydrogen atom or a C 1-6 alkyl group, R 3 is a hydrogen atom, a C 1-6 alkyl group or the like, R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, R 7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C 3-8 cycloalkyl group, an amino group which may have a substituent or a C 1-6 alkoxy group which may have a substituted group, M 1 is a single bond, a C 1-4 alkylene group or the like, Y is N or CR F (in the formula, and R F represents a hydrogen atom, a C 1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.
    以下通式(I)所表示的尿素衍生物具有V2受体激动剂作用,可用于治疗或预防尿崩症、夜尿症、夜间遗尿、过度活动膀胱等疾病。在该通式中,R1表示氢原子或C1-6烷基,可以有取代基;R2表示氢原子或C1-6烷基;R3表示氢原子、C1-6烷基或类似物;R4、R5和R6独立地表示氢原子、卤素原子或类似物;R7表示氢原子、可以有取代基的杂环芳基、C3-8环烷基、可以有取代基的氨基或可以有取代基的C1-6烷氧基;M1表示单键、C1-4烷基等;Y表示N或CRF(在该式中,RF表示氢原子、C1-6烷基或类似物);以及其药学上可接受的盐、前药或包含它们的制剂,以及其医药用途。
  • Organocatalytic Asymmetric Synthesis of Bridged Tetrahydrobenzo[<i>b</i>]azepines/oxepines
    作者:Jiaming Zou、Lei Xu、Yurong Tang、Wentao Wang、Yunfei Cai
    DOI:10.1021/acs.orglett.2c02833
    日期:2022.10.7
    The asymmetric synthesis of bridged tetrahydrobenzo[b]azepine and oxepine derivatives through chiral Brønsted acid catalyzed asymmetric aza-Piancatelli rearrangement/Michael addition sequence has been developed. The reaction proceeds under mild reaction conditions to afford the final bridged cyclic products in good yields with excellent enantio- and diastereoselectivities.
    通过手性 Brønsted 酸催化的不对称氮杂-Piancatelli 重排/Michael 加成序列,开发了桥联四氢苯并 [ b ]azepine 和 oxepine 衍生物的不对称合成。该反应在温和的反应条件下进行,以良好的收率提供最终的桥接环状产物,并具有出色的对映和非对映选择性。
  • Asymmetric 2,4-Dienylation/[4 + 2] Annulation Cascade to Construct Fused Frameworks via Auto-Tandem Palladium Catalysis
    作者:Jian-Xiang Zhu、Fu Pi、Teng Sun、Wen-Yu Huang、Lu Gao、Zhi-Chao Chen、Wei Du、Ying-Chun Chen
    DOI:10.1021/acs.orglett.3c01084
    日期:2023.5.26
    4-dienylation/Michael addition/π–σ–π isomerization/allylic alkylation. A broad array of enantioenriched architectures having fused and spirocyclic frameworks are constructed in moderate to excellent yields and stereoselectivity. Notably, the intrinsic intramolecular Diels–Alder reaction pattern of the dienylated intermediates is well reversed via Pd(0)−π–Lewis base catalysis.
    已提出邻位官能化芳基烯酮和 2,4-二烯基碳酸酯之间的钯催化串联反应,通过连续的 2,4-二烯化/迈克尔加成/π-σ-π 异构化/烯丙基烷基化进行。大量具有融合和螺环框架的对映体富集结构以中等到优异的产率和立体选择性构建。值得注意的是,二烯化中间体的固有分子内 Diels-Alder 反应模式可通过 Pd(0)-π-Lewis 碱催化得到很好的逆转。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐